Co-Delivery of Autoantigen and B7 Pathway Modulators Suppresses Experimental Autoimmune Encephalomyelitis
Journal Title: The AAPS Journal - Year 2014, Vol 16, Issue 6
Abstract
The online version of this article (doi:10.1208/s12248-014-9671-y) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Laura Northrup, Joshua O. Sestak, Bradley P. Sullivan, Sharadvi Thati, Brittany L. Hartwell, Teruna J. Siahaan, Charlotte M. Vines, Cory Berkland
Keywords
Related Articles
- EP ID EP681728
- DOI 10.1208/s12248-014-9671-y
- Views 107
- Downloads 0
Toward Global Standards for Comparator Pharmaceutical Products: Case Studies of Amoxicillin, Metronidazole, and Zidovudine in the Americas
The online version of this article (doi:10.1208/s12248-012-9350-9) contains supplementary material, which is available to authorized users.
Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation
Pharmacokinetic (PK) and pharmacodynamic (PD) modeling and simulation (M&S) are well-recognized powerful tools that enable effective implementation of the learn-and-confirm paradigm in drug development. The impac...
Dashboard Systems: Implementing Pharmacometrics from Bench to Bedside
In recent years, there has been increasing interest in the development of medical decision-support tools, including dashboard systems. Dashboard systems are software packages that integrate information and calculations a...
Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?
CT-P13, the world’s first biosimilar monoclonal antibody to infliximab, was approved for marketing in South Korea for all the six indications of infliximab, which Europe may follow, although the product was teste...
Erratum to: Translational Biomarkers: from Preclinical to Clinical a Report of 2009 AAPS/ACCP Biomarker Workshop
The online version of the original article can be found at 10.1208/s12248-011-9265-x.